Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia
Wioleta M Zelek, Ryan J Bevan, Bryan Paul Morgan · 2025
Read Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia by Wioleta M Zelek, Ryan J Bevan, Bryan Paul Morgan (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713514.txt.
Description
Wioleta Zelek, Ryan Bevan, and Bryan Paul Morgan published this mouse study in two thousand twenty-five on a part of the immune system called complement. In Alzheimer's disease, complement can run out of control and harm the brain's own cells.
The team focused on the membrane attack complex, a weapon the system builds to kill cells. They bred Alzheimer's-model mice that could not make a key part of that weapon, called C7. Those mice had less immune overdrive, less amyloid, more nerve links, and better scores on thinking tests. A drug-like antibody that blocks C7 gave like gains in normal model mice after four weeks of treatment. The authors say blocking this one step could shield the brain. They present it as a path worth testing for human treatment.
Catalog record
| CREATOR | Wioleta M Zelek, Ryan J Bevan, Bryan Paul Morgan |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |